Literature DB >> 1997505

Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy.

A H Lockwood1, E W Yap, H M Rhoades, W H Wong.   

Abstract

We measured CBF and the CMRglc in normal controls and in patients with severe liver disease and evidence for minimal hepatic encephalopathy using positron emission tomography. Regions were defined in frontal, temporal, parietal, and visual cortex; the thalamus; the caudate; the cerebellum; and the white matter along with a whole-slice value obtained at the level of the thalamus. There was no difference in whole-slice CBF and CMRglc values. Individual regional values were normalized to the whole-slice value and subjected to a two-way repeated measures analysis of variance. When normalized CBF and CMRglc values for regions were compared between groups, significant differences were demonstrated (F = 5.650, p = 0.00014 and F = 4.58, p = 0.0073, respectively). These pattern differences were due to higher CBF and CMRglc in the cerebellum, thalamus, and caudate in patients and lower values in the cortex. Standardized coefficients extracted from a discriminant function analysis permitted correct group assignment for 95.5% of the CBF studies and for 92.9% of the CMRglc studies. The similarity of the altered pattern of cerebral metabolism and flow in our patients to that seen in rats subjected to portacaval shunts or ammonia infusions suggests that this toxin may alter flow and metabolism and that this, in turn, causes the clinical expression of encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997505     DOI: 10.1038/jcbfm.1991.66

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  41 in total

Review 1.  Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

3.  Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics.

Authors:  Alan H Lockwood; Karin Weissenborn; Martin Bokemeyer; U Tietge; Wolfgang Burchert
Journal:  Metab Brain Dis       Date:  2002-03       Impact factor: 3.584

Review 4.  Positron emission tomography in the study of hepatic encephalopathy.

Authors:  Alan H Lockwood
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 5.  Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy.

Authors:  Laurent Spahr; Pierre R Burkhard; Hannelore Grötzsch; Antoine Hadengue
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 6.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 7.  The basal ganglia and portal-systemic encephalopathy.

Authors:  K Weissenborn; H Kolbe
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

8.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

Review 9.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

10.  Role of Magnetic Resonance in Understanding the Pathogenesis of Hepatic Encephalopathy.

Authors:  A Huda; R K Gupta; N Rajakumar; M A Thomas
Journal:  Magn Reson Insights       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.